Search results
Showing 181 to 195 of 729 results for innovative
Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.
Pirfenidone for treating idiopathic pulmonary fibrosis (TA504)
Evidence-based recommendations on pirfenidone (Esbriet) for idiopathic pulmonary fibrosis in adults.
Healthy.io test for home testing of urine albumin to creatinine ratio (MIB221)
NICE has developed a medtech innovation briefing (MIB) on Healthy.io test for home testing of urine albumin to creatinine ratio .
Day-to-day decision making is the responsibility of NICE's executive team.
How to use NICE guidance to reduce health inequalities during and after pregnancy.
How to use NICE guidance to reduce health inequalities in people experiencing cardiovascular disease (CVD).
Evidence-based recommendations on risdiplam (Evrysdi) for 5q spinal muscular atrophy (SMA) in people of all ages.
Evidence-based recommendations on imlifidase (Idefirix) for desensitisation treatment before kidney transplant in people with chronic kidney disease.
Bosutinib for previously treated chronic myeloid leukaemia (TA401)
Evidence-based recommendations on bosutinib (Bosulif) for previously reated chronic myeloid leukaemia in adults.
Evidence-based recommendations on talquetamab (Talvey) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults.
Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)
Evidence-based recommendations on vedolizumab (Entyvio) for treating moderate to severe ulcerative colitis in adults.
Ocrelizumab for treating primary progressive multiple sclerosis (TA585)
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis in adults.
Cabozantinib for previously treated advanced renal cell carcinoma (TA463)
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma in adults.
Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.